Histone demethylase KDM5D drives sex-specific differences in colorectal cancer
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Introduction

Sex-specific differences in cancer outcomes are
observed in CRC, with males typically being more
adversely affected than females. While sex differences
have been correlated with risk factors and sex hormone
differences1, molecular and biological mechanisms
underlying such correlations have not been identified
nor genetically validated. In this regard, the Y
chromosome contains a small number of protein-coding
genes that, except for sex-determination genes, have
received limited attention as potential determinants of
cancer hallmarks and clinical outcomes.
The most common genetic alterations in sporadic
human CRC include activating mutations of the KRAS
oncogene and inactivating mutations or deletion of the
APC and TP53 tumor suppressors2. A GEMM of CRC
with these signature alterations, “iKAP”, recapitulates
the evolution of CRC from adenoma to adenocarcinoma
to invasive and metastatic diseases, and established
that KRAS mutation (KRAS*) drives CRC invasiveness
and metastasis and its extinction eliminates invasive
and metastatic diseases3,4.

Aim

Integrating GEMM platform and patient data analyses to
identify key genes regulating mutant KRAS-driven sex
differences in CRC invasion and metastasis.

Results

3. KDM5D impairs tight junction through epigenetically repressing AMOT.
1. KDM5D is correlated with sex-specific KRAS* CRC metastasis.
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Figure 1. a, Overall survival (OS) analyses of iKAP and iAP mice. b, OS analyses of CRC
patients from Colorectal Cancer Subtyping Consortium. c, Intersecting analysis of differentially
expressed genes in male iKAP tumors. Fold change > 1.5 and p-value < 0.05. d, qPCR for
Kdm5d expression in male iKAP cell lines derived from primary tumor (3346) and matched liver
metastasis (L2-3). e, f, Expression of KDM5D in male CRC patients.

Figure 3. a, Heatmaps of H3K4me2/3 levels around transcription start sites (TSSs) in iKAP
cells. b, Intersecting analysis of differential genes. c, qPCR of Amot in iKAP cells. d,
Representative images of transmission electron microscopy imaging of tight junctions between
epithelial cells in primary tumors from GEMMs. Tumors were collected on 102-104 days after
induction.
4. KDM5D represses MHC class I antigen processing and presentation.
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2. Kdm5d transgene expression promotes tumor invasiveness and metastasis.

Materials and Methods

1. Sex-stratified Kaplan-Meier survival analyses,
mutation analyses and transcriptomic analyses in
CRC patients, iKAP GEMM tumors and CCLE
database.
2. Transcriptomic (RNA-seq) and epigenomic (ChIPseq and Hi-ChIP) analyses of iKAP tumors and
derived cancer cell lines.
3. Histopathological studies and IHC of GEMM tumors.
4. Molecular biology studies (western blot, qPCR, IF
and co-IP) of iKAP cell lines.
5. Cell culture-based functional studies (luciferase
reporter assay, migration assay, cell junction
permeability assay and flow cytometry) in iKAP cell
lines.
6. Transmission electron microscopy of GEMM tumors.
7. T cells killing assay using iKAP cell lines and OT-1
CD8+ T cells
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Though KDM5D and its X chromosome paralog
KDM5C share structural and functional similarity,
we have excluded the possibility that KDM5D and
KDM5C function coincidentally in KRAS* CRC
with the evidence that (i) KDM5C is not regulated
by KRAS*, (ii) KDM5C is not differentially
expressed in CRC primary vs. metastatic tumors,
and (iii) KDM5C does not regulate KDM5D
downstream genes.
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Figure 2. a, Schemes of iAP, iAP-KDM5D and iKAP GEMMs. b, qPCR of Kdm5d transgene in
FFPE tissues of primary tumors from female mice. c, Representative images of the most invasive
primary tumors and/or LN and distal metastases in GEMMs. iAP: female; iAP-KDM5D: female;
iKAP: male. d, Percentage of TNM stages of tumors.

Discussion

Figure 4. a, Super-enhancers ranked by H3K27ac signal in iKAP cells. b, Intersecting analysis of
all MHC cluster genes that were downregulated in L2-3 vs. 3346 and upregulated in KO and that
have human orthologs. c, qPCR of Tap1 and Tap2 in iKAP cells. d, Percentage of dead iKAP cells
(GFP+ for iKAP cells and SYTOX Blue+ for dead cells) in CD8+ T cell killing assay. iKAP cells
were pretreated with 2 mg of ovalbumin protein and +/- 10ng/ml IFN-γ for 24 hours. iKAP cells
were re-plated +/- activated OT-1 CD8+ T cells at the ratio of effector: target = 10: 1. e,
Quantitation of the number of CD8+ cells at the tumor invasive front detected by IHC in primary
tumors with comparable invasiveness (later pTis and pT1). f, Representative images of IHC for
CD8 at the tumor invasive front.
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